全文获取类型
收费全文 | 1775644篇 |
免费 | 146733篇 |
国内免费 | 3154篇 |
专业分类
耳鼻咽喉 | 23668篇 |
儿科学 | 57650篇 |
妇产科学 | 49911篇 |
基础医学 | 250489篇 |
口腔科学 | 51179篇 |
临床医学 | 158017篇 |
内科学 | 351545篇 |
皮肤病学 | 36426篇 |
神经病学 | 147260篇 |
特种医学 | 70411篇 |
外国民族医学 | 487篇 |
外科学 | 270960篇 |
综合类 | 42700篇 |
现状与发展 | 5篇 |
一般理论 | 821篇 |
预防医学 | 139745篇 |
眼科学 | 40170篇 |
药学 | 133480篇 |
3篇 | |
中国医学 | 3259篇 |
肿瘤学 | 97345篇 |
出版年
2018年 | 18205篇 |
2017年 | 14402篇 |
2016年 | 15811篇 |
2015年 | 18400篇 |
2014年 | 25850篇 |
2013年 | 38999篇 |
2012年 | 53538篇 |
2011年 | 56831篇 |
2010年 | 33150篇 |
2009年 | 31462篇 |
2008年 | 54375篇 |
2007年 | 57314篇 |
2006年 | 57659篇 |
2005年 | 56690篇 |
2004年 | 55616篇 |
2003年 | 53035篇 |
2002年 | 51706篇 |
2001年 | 77313篇 |
2000年 | 79578篇 |
1999年 | 68094篇 |
1998年 | 20056篇 |
1997年 | 18342篇 |
1996年 | 18160篇 |
1995年 | 17656篇 |
1994年 | 16539篇 |
1993年 | 15604篇 |
1992年 | 56434篇 |
1991年 | 54772篇 |
1990年 | 53439篇 |
1989年 | 51643篇 |
1988年 | 48069篇 |
1987年 | 47431篇 |
1986年 | 45127篇 |
1985年 | 43750篇 |
1984年 | 33294篇 |
1983年 | 28806篇 |
1982年 | 17678篇 |
1981年 | 15807篇 |
1980年 | 14871篇 |
1979年 | 31161篇 |
1978年 | 21887篇 |
1977年 | 18577篇 |
1976年 | 17410篇 |
1975年 | 18162篇 |
1974年 | 22044篇 |
1973年 | 21180篇 |
1972年 | 19234篇 |
1971年 | 18071篇 |
1970年 | 16593篇 |
1969年 | 15488篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献62.
James Milligan Joseph Lee Matt Smith Lindsay Donaldson Peter Athanasopoulos Kent Bassett-Spiers 《The journal of spinal cord medicine》2020,43(2):223-233
Context: Persons with spinal cord injury (SCI) experience significant challenges when they access primary care and community services.Design: A provincial summit was held to direct research, education, and innovation for primary and community care for SCI.Setting: Toronto, Ontario, Canada.Participants: Key stakeholders (N?=?95) including persons with SCI and caregivers, clinicians from primary care, rehabilitation, and specialized care, researchers, advocacy groups, and policy makers.Methods: A one-day facilitated meeting that included guest speakers, panel discussions and small group discussions was held to generate potential solutions to current issues related to SCI care and to foster collaborative relationships to advance care for SCI. Perspectives on SCI management were shared by primary care, neurosurgery, rehabilitation, and members of the SCI communityOutcome Measures: Discussions were focused on five domains: knowledge translation and dissemination, application of best practices, communication, research, and patient service accessibility.Results: Summit participants identified issues and prioritized solutions to improve primary and community care including the creation of a network of key stakeholders to enable knowledge creation and dissemination; an online repository of SCI resources, integrated health records, and a clinical network for SCI care; development and implementation of strategies to improve care transitions across sectors; implementation of effective care models and improved access to services; and utilization of empowerment frameworks to support self-management.Conclusions: This summit identified priorities for further collaborative efforts to advance SCI primary and community care and will inform the development of a provincial SCI strategy aimed at improving the system of care for SCI. 相似文献
63.
64.
65.
66.
67.
68.
Past research suggests that as many as 50% of onward human immunodeficiency virus (HIV) transmissions occur during acute and recent HIV infection. It is clearly important to develop interventions which focus on this highly infectious stage of HIV infection to prevent further transmission in the risk networks of acutely and recently infected individuals. Project Protect tries to find recently and acutely infected individuals and prevents HIV transmission in their risk networks. Participants are recruited by community health outreach workers at community-based HIV testing sites and drug users' community venues, by coupon referrals and through referrals from AIDS clinics. When a network with acute/recent infection is identified, network members are interviewed about their risky behaviors, network information is collected, and blood is drawn for HIV testing. Participants are also educated and given prevention materials (condoms, syringes, educational materials); HIV-infected participants are referred to AIDS clinics and are assisted with access to care. Community alerts about elevated risk of HIV transmission are distributed within the risk networks of recently infected. Overall, 342 people were recruited to the project and screened for acute/recent HIV infection. Only six index cases of recent infection (2.3% of all people screened) were found through primary screening at voluntary counseling and testing (VCT) sites, but six cases of recent infection were found through contact tracing of these recently infected participants (7% of network members who came to the interview). Combining screening at VCT sites and contact tracing the number of recently infected people we located as compared to VCT screening alone. No adverse events were encountered. These first results provide evidence for the theory behind the intervention, i.e., in the risk networks of recently infected people there are other people with recent HIV infection and they can be successfully located without increasing stigma for project participants. 相似文献
69.
70.
I. R. Reid 《Journal of internal medicine》2015,277(6):690-706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area. 相似文献